Amgen Q1 Preview: What to expect
📅 Amgen (AMGN) is scheduled to report its Q1 earnings results on April 30 after the closing bell.
💰 Analysts project a consensus EPS estimate of $4.77, indicating a nearly 3% decline from the previous period.
📈 Revenue is expected to reach $8.57 billion, representing a 5.8% year-over-year increase.
🏢 The preview article was published by Seeking Alpha on April 29, 2026.
👩💼 Nivedita Hazra served as the news editor and author for this earnings preview report.
📊 Market analysts anticipate slight downside pressure on per-share earnings despite revenue growth.
Bullish Signals
- Amgen (AMGN) is projected to deliver nearly 6% year-over-year revenue growth of $8.57 billion for Q1.
- The company anticipates a quarterly top-line increase driven by its core business segments ahead of the April 30 report date.
Risk Factors
- Amgen is projected to report a nearly 3% fall in its Q1 earnings (EPS), with the consensus estimate at $4.77.
- The company faces expectations of declining profitability even as revenue grows, creating a potential disconnect between top-line growth and bottom-line performance.
Full Analysis
Amgen Inc. (NASDAQ: AMGN) is expected to release its Q1 earnings report on April 30, after the closing bell. Analysts project an earnings per share (EPS) decrease of nearly 3% compared to the previous quarter, with a consensus EPS estimate of $4.77. Revenue is anticipated to grow by 5.8% year-over-year, reaching an estimated $8.57 billion. The preview also notes that Q4 results are relevant context for this quarter's reporting, though specific Q4 figures in the article text appear truncated or summarized within the introductory snippet.
